We have some exciting news to share! The Motley Fool UK has now become an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. We’ll be introducing a new name and brand over the coming weeks — we're very excited to share it with you and embark on this new chapter together!

Are these 3 top stocks still mighty income machines?

The search for a higher yield on your savings should start with these three stocks, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Everybody needs a few income machines to keep their portfolio ticking over. Here are three you can’t afford to ignore.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK) has been called an income machine for as long as I can remember and despite the odd glitch it keeps pumping out the dividends. The share price has also impressed lately, growing 20% in the past three months, which has knocked the yield to 4.81%. Given that this is almost 20 times the current base rate, it seems churlish to complain.

Glaxo’s 4% increase in turnover over the second quarter (at constant exchange rates) and 16% leap in core earnings per share (EPS) satisfied markets. Key to the company’s long-term prospects are sales from new products and here the news is good, as they now account for 23% of total pharmaceutical sales, offsetting continuing declines in Seretide/Advair. The dividend has been frozen at 80p for several years but is still a tonic in today’s low yield world.

Royal Mail

Royal Mail (LSE: RMG) is a relatively new income play but looks set to keep churning out the dividends for years to come. The existential question is whether its parcels business can expand fast enough to overcome the inevitable decline in the old-fashioned letter. Its latest trading update showed a 1% rise in group revenue, offsetting a 1% decline in UK revenues, exciting nobody either way. 

Similarly, a 2% rise in parcels volumes and revenues had to be judged against the 2% drop in UK addressed letter volumes and 3% drop in letter revenues. Double-digit growth in Europe suggests Royal Mail could deliver some excitement but the general message is ‘slow and steady goes’, amid challenging economic seas. This impression is confirmed by forecast EPS growth of 0% until March 2017, followed by 3% in 2018. But a forecast dividend of 4.7% is attractive and healthy cover make this a good buy for income seekers, especially at 12.48 times earnings.

Vodafone Group

The phrase income machine could almost have been coined for mobile phone giant Vodafone (LSE: VOD). It continues to do what it has done for as long as I can recall, that to yield around 5% a year. Right now you get 4.87%, pretty much in range. The share price is up 44% over the past five years, which is solid for a company that few people buy for its growth prospects.

First quarter revenues grew 2.2%, although they fell 4.5% in reported terms on negative foreign exchange movements, as Vodafone reports in euros. It has made big strides in selling larger data bundles and fixed broadband services across its key markets, with a whopping 63% growth in data traffic across the quarter, plus an extra 5.7m on its 4G customer base, which has doubled year-on-year to 52.5m. Data revenues, however, aren’t rising at anything like that pace and despite rapid growth in Turkey and India, Europe continues to hold the business back. That said, forecast EPS growth of 38% in the year to March 2017 and 13% the year after is promising. By then the stock is expected to yield 5.1%, which is pretty much what you would expect.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British pound data
Investing Articles

2 UK shares to consider avoiding as the FTSE 100 extends losses

As the FTSE 100 dips for the second time this year, Mark Hartley weighs up market sentiment and considers two…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

How to invest £125 a month in UK shares to target a £39,039 annual passive income

Muhammad Cheema explains how an investor could earn the current median salary in the UK as passive income by making…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

These white-hot FTSE 250 growth shares are on sale today!

Royston Wild loves a good bargain. Here he reveals two FTSE 250 shares that all savvy UK stock investors should…

Read more »

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

How much do you need an ISA for a £31,352 second income?

Investing regularly in a Stocks and Shares ISA can generate a significant second income in retirement. Royston Wild explains how.

Read more »

Aston Martin DBX - rear pic of trunk
Investing Articles

With the Aston Martin share price in pennies, is it in bargain territory?

With the Aston Martin share price at a fraction of what it once was, is it a bargain? Our writer…

Read more »

A hiker and their dog walking towards the mountain summit of High Spy from Maiden Moor at sunrise
Investing Articles

How I plan to lock in sustainable growth on the FTSE 100 in the coming years

Mark Hartley takes a sobering look at the future, and outlines a plan to target FTSE 100 sectors with lower…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

What are the FTSE’s most lucrative high-yield shares?

Our writer zooms in one one of a handful of high-yield FTSE 100 shares to explain why he thinks it…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

Why bother with a SIPP now rather than wait 10 years?

Interested in a SIPP but putting it off to give yourself time to think? Christopher Ruane explains why that could…

Read more »